| Structure and Function | Research | Products | Contact |
 BReMeL, an innovative Hellenic Biotechnology Company (under-establishment) will be based in Thessaloniki, and in full operation will include three Departments: Commercial - Scientific - Educational. We envisage that the achievement of the Company's goals concerning the production of Biopharmaceuticals and Products of Regenerative Medicine has in the long term the potential of changing the "landscape" in the field of the Greek Pharmaceutical Industry and Medical Biotechnology Research. In the past, BReMeL's existing investment project for the production of three raw biopharmaceutical materials in purified form (recombinant insulin, recombinant HBsAg, penicillin) had been selected for funding by the European Program NSRF 2007-2013 with the maximum allowable amount of € 290.000,00, characterized as "extremely dynamic" and its innovation was graded with excellent (20/20). |
 a) Development of a new therapeutic strategy for the safer and more efficient administration of anti-CD19 CAR T-cells to refractory B-acute lymphoblastic leukemia. b) Generation of a specialized cell line from human Langerhans beta-cells for insulin production.c) Formation of experimental cellular models - disease modeling - by inducing the differentiation of mesenchymal stem cells (MSCs) or induced pluripotent cells (iPSCs), in order to study the pathophysiological mechanisms of incurable diseases such as neurodegenerative diseases, heart diseases, etc. and test new drugs. |
 The Greek Pharmaceutical Industry does not produce any active pharmaceutical ingredients (APIs) at all and only formulates the imported ones. Therefore, the survival of the corresponding domestic drug production depends exclusively on APIs imports from international markets, mostly India and China. The primary target for BReMeL is to become the first domestic company for production on a massive scale of:(a) APIs in a purified form for the production of biopharmaceuticals according to the specifications of the corresponding monographs of the European Pharmacopoeia VIII (Ph.Eur VIII), making use of the "cellular factory" of micro-organisms and the recombinant DNA technology. (b) Regenerative medicine products by applying innovative methods of Cellular and Molecular Biology. |
 For more information on BReMeL, you can contact via the contact form, by e-mail or phone. |
 |
|
|
|
Welcome to BReMeL!!
We welcome you to the BReMeL's website, a new under-establishment Greek company for the development of biotechnology products for use in medical practice and research.
A journey to CAR-T cell therapy
- “Problems with the CAR-T therapy do not seem to be with the cell products, per se, but with the current therapeutic strategy”.
- “Do not keep moving forward, but take the reverse pathway”.
1o video: Title: An innovative solution to harness the promising anticancer potential of CAR T cells - Part A: Current status
A comprehensive description of the most important points of anti-CD19 CAR-T cell therapy, for the treatment of B-hematological malignancies (primarily resistant / relapsed B-acute lymphoblastic leukemia, R/R B-ALL). The current approaches result in either a partial/complete but (as a rule) short-term remission, or a therapeutic deadlock (disease relapses) (upload).
A comprehensive description of the most important points of anti-CD19 CAR-T cell therapy, for the treatment of B-hematological malignancies (primarily resistant / relapsed B-acute lymphoblastic leukemia, R/R B-ALL). The current approaches result in either a partial/complete but (as a rule) short-term remission, or a therapeutic deadlock (disease relapses) (upload).
2o video: Title: An innovative solution to harness the promising anticancer potential of CAR T cells - Part B: The BaSiC-cel method
A detailed description of BaSiC-cel, an innovative therapeutic approach to treat these diseases with anti-CD19 CAR-T cells. The primary goal of the method is the complete elimination of the two most serious side effects caused by the activation of CAR-T cells, namely CRS and ICANS *.
* this video will be uploaded shortly after receiving the priority date from the European Patent Office.
A detailed description of BaSiC-cel, an innovative therapeutic approach to treat these diseases with anti-CD19 CAR-T cells. The primary goal of the method is the complete elimination of the two most serious side effects caused by the activation of CAR-T cells, namely CRS and ICANS *.
* this video will be uploaded shortly after receiving the priority date from the European Patent Office.
